Pellets are small cylinders implanted under the skin that release testosterone over several months. Understanding these patterns can help explain why some people develop high hemoglobin and others do not. People sometimes try donating blood without medical guidance to manage high hemoglobin. These steps help stabilize hemoglobin but should be used together with medical treatment, not as replacements. If hemoglobin or hematocrit rises to a level considered too high, doctors may recommend therapeutic phlebotomy. Not drinking enough water can make hemoglobin appear higher because the blood becomes more concentrated. Treating sleep apnea with CPAP therapy or weight loss often leads to lower hemoglobin.
The safety implications of increases in neutrophil and monocyte counts during testosterone treatment need further investigation, particularly given the ongoing controversy regarding the cardiovascular safety of testosterone therapy34. Complete blood counts were measured at baseline, and during months 3 and 6. Because of the known association of increased leukocyte15–18 and platelet counts19–21 with cardiovascular and thromboembolic risk, these findings, if confirmed in human studies, could affect the safety of testosterone treatment. Testosterone is well known to increase circulating hemoglobin, hematocrit and erythrocyte count1–6, and erythrocytosis is a well-recognized adverse effect of testosterone treatment. If you have a high red blood cell count, it’s important to talk to your healthcare provider. Most of the time, people don’t know they have a high red blood cell count.
Here we performed longitudinal systems-level analyses in 23 trans men and found that testosterone modulates a cross-regulated axis between type-I interferon and tumour necrosis factor. Females respond more strongly to vaccines, and adverse reactions are more frequent3, like most autoimmune diseases4. Infectious, inflammatory and autoimmune conditions present differently in males and females. Regular communication, steady follow-up, and a shared plan of care make TRT a therapy that you can maintain with confidence over time. Understanding your lab results, knowing what symptoms to watch for, and taking action early all help keep your health on track.
Gels and patches tend to raise hematocrit less than injections. Intervention usually depends on how high the levels are and whether symptoms are present. This cutoff is widely used because research shows that the risk of complications increases more clearly at 54% and above. Most guidelines agree that a hematocrit of 54% or higher is the point where TRT should not continue without intervention. Doctors may simply re-check levels, ask about symptoms, or make small changes.
Because of this, TRT can cause hemoglobin and hematocrit to rise, sometimes to levels that need medical attention. These blood markers are a key part of long-term safety, and understanding them is essential for anyone using testosterone therapy. In particular, TRT often changes levels of hemoglobin and hematocrit.
Your hemoglobin and hematocrit will be checked at baseline, then again at 3 months, 6 months, and yearly. But TRT also affects your blood system, especially your hemoglobin and hematocrit levels. One of the most important safety issues during testosterone therapy is the rise in hemoglobin and hematocrit. When TRT is added, the stimulation of red blood cell production may cause hemoglobin to rise faster than expected. Blood thickness, or viscosity, does increase when red blood cell levels rise. High hemoglobin and high hematocrit are two of the most common side effects of testosterone replacement therapy (TRT). A higher testosterone dose causes a stronger boost in red blood cell production.
People also often search online to understand how serious these blood changes are. That is why doctors require regular blood tests while a person is on TRT. Thicker blood flows more slowly and may increase strain on the heart and blood vessels. These changes are not rare, and careful monitoring is one of the most important steps in safe treatment. Together, these markers help doctors understand how well your blood is transporting oxygen and how thick or "dense" your blood is.
A case of a trans woman developing lupus during oestradiol therapy46 points towards direct potentiating effects of oestradiol on IFN-I responses. Similar cross-regulation has been described in vitro39 and in vivo in healthy volunteers40, and in patients with female-dominated autoimmune lupus41, but its regulation by sex hormones is not previously known. Here we describe several layers of immunological adaptations in trans men, assigned female sex at birth and undergoing masculinizing testosterone treatment. In contrast, after 24 h of mTB in vitro, secondary signals, such as monocyte-derived IL-6, TNF, IL-15 and IL-12B, are likely to influence, and in this case female NK cells have markedly reduced IFNγ mRNA, whereas male NK cells sustain a high IFNγ response transcriptionally (Fig. 5h).

Gender: Female

Social links